

Efficient GMP-compliant expansion of mesenchymal stromal cells (MSCs) from umbilical cord, bone marrow, and adipose tissue using a closed cultivation system



Bundesministerium für Bildung und Forschung

Permanent Poster Number 256

K. Godthardt¹, C. Heifer¹, F. Jüngerkes¹, S. Petri², R. Esser³, A. Bosio¹, and S. Knöbel¹ / ¹Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, ²Department of Neurology, Hannover Medical School, Hannover, Germany, ³Institute of Cellular Therapeutics/ATMP GMP-Development Unit, Hannover Medical School, Hannover, Germany

Introduction

Human mesenchymal stromal cells (MSCs) hold great promise for clinical use and cell therapy applications and can be isolated from multiple tissue, e.g., bone marrow (BM), umbilical cord (UC), and adipose tissue (AT). To ensure highest quality and safety of the resulting cellular products, MSCs have to be maintained using standardized cultivation conditions and procedures. To this end, we have developed the xeno-free MSC-Brew GMP Medium following the recommendations of USP <1043> on ancillary materials, thus enabling isolation and expansion of MSCs from various tissue sources for use in clinical research. To increase the level of process standardization and product safety we developed the CliniMACS Prodigy[®] Adherent Cell Culture System for automated and GMP-compliant isolation and cultivation of adherent cells using a closed single-use tubing set.

The process includes the following modules, which can be combined as required:

- Density gradient centrifugation (DGC)
- Surface coating
- Inoculation
- Culture
- Media change
- Harvest
- Here we show that MSCs from different tissue sources can be expanded and

Characterization of MSCs

To confirm the quality of the cells processed with the CliniMACS Prodigy, MSC marker expression was analyzed using flow cytometry. MSCs met ISCT criteria, since the cells showed high expression levels of CD73, CD90, and CD105, while CD14, CD20, CD34, CD45 (Non-MSC), and HLA-DR expression levels were low¹ (tab. 1).



		tissue	
Positive mark	ers (ISCT Guid	eline >95 %)	
99.71±0.47	99.89±0.06	99.86±0.07	
99.78±0.36	99.45±0.20	99.53±0.24	
99.70±0.40	99.78±0.06	99.44±0.42	
Negative markers (ISCT Guideline <2 %)			
0.64±0.05	1.33±0.34	1.19±05	
0.22±0.01	0.42±0.17	0.34±0.20	
	99.71±0.47 99.78±0.36 99.70±0.40 Negative mark 0.64±0.05 0.22±0.01	99.71±0.47 99.89±0.06 99.78±0.36 99.45±0.20 99.70±0.40 99.78±0.06 Negative markers (ISCT Guid 0.64±0.05 1.33±0.34 0.22±0.01 0.42±0.17	

passaged from primary tissue or single-cell suspensions using the CliniMACS Prodigy Adherent Cell Culture System, combining the process modules in a flexible way.

Methods

Manufacturing of MSCs using the CliniMACS Prodigy[®] Adherent Cell Culture System

The CliniMACS Prodigy[®] provides a range of ports for connecting bags containing buffer, media, reagents, and cellular material. Various tubing sets allow for a multitude of applications. For this cultivation process, we chose the tubing set CliniMACS Prodigy TS 730, which provides up to eight connections for bags. This setup also offers the option to pre-warm solutions during transfer from an external 4 °C storage compartment to the cultivation and centrifugation unit (CCU) as well as external tissue culture vessels (ECVs) which are connected to the tubing set and are placed in an incubator next to the CliniMACS Prodigy (fig. 1A). Bags can be connected in a sterile manner prior to the installation procedure or later via sterile welding during the manufacturing process. Cellular starting material (BM aspirate, dissociated UC or adipose tissue-MSCs (AT-MSCs)) is provided in the application bag (bag 1) of the tubing set. Density gradient centrifugation (DGC) of BM aspirate is performed automatically by the system, while the preparation of tissues like UC and AT is performed outside of the system. After tissue preparation all following steps are performed semi-automatically by the CliniMACS Prodigy Adherent Cell Culture System, including the initial expansion step in the CCU or an ECV as well as all liquid handling steps, i.e., inoculation, washing of cells, medium exchange, and cell harvest (fig. 1B). Moreover, the system offers the possibility of taking samples to determine the cell number and analyze marker expression.



Suppression of T cell proliferation

T cell–suppression potential of MSCs was analyzed using flow cytometry. To this end, CD4⁺CD25⁻T cells were isolated from whole blood by MACS[®] Cell Separation Technology and labeled with a cell tracking dye to monitor T cell division after

stimulation with particles loaded with CD2, CD3, and CD28 antibodies. T cells were cocultured with MSCs in different ratios and showed a T cell–suppressive potential at all conditions (fig. 3).

Figure 3



Umbilical cord



Results

В

Different human starting materials were used and processed to isolate and expand MSCs using the CliniMACS Prodigy[®] Adherent Cell Culture System. I) BM aspirate was processed directly within the closed system of the CliniMACS Prodigy by performing a DGC to isolate BM-mononuclear cells (BM-MNCs), which were then further cultivated to isolate MSCs by plastic adherence. II) UC was dissociated using the gentleMACS[™] Dissociator together with the Umbilical Cord Dissociation Kit to obtain single cells. These cells were then transferred to the CliniMACS Prodigy and seeded for the isolation of MSCs. Here, the surface of the CCU was coated with Laminin 521. III) AT-MSCs, which can be ob-

tained from the stromal vascular fraction (SVF) isolated from lipoaspirate by, e.g., enzymatic digestion, were pre-expanded prior to transfer to the CliniMACS Prodigy. Subsequently, all steps were performed within the closed system of the CliniMACS Prodigy for cultivation of cells.

For comparison, isolation and expansion were performed manually using standard tissue culture vessels. Proliferation data showed comparable results across all tissues (fig. 2A). Furthermore, cells showed a typical MSC morphology (fig. 2B).

Expansion of MSCs using the CliniMACS Prodigy[®] Adherent Cell Culture System

Figure 2						
А	Bone marrow		Umbilical cord		Adipose tissue	
	CliniMACS Prodigy Donor 1 Donor 2 Donor 3 Donor 4	manual processing — Donor 1 — Donor 2	CliniMACS Prodigy Donor 1 Donor 2 Donor 3	manual processing Donor 1 Donor 2 Donor 3	CliniMACS Prodigy — Donor 1 — Donor 2 — Donor 3	manual processing Donor 1 Donor 2 Donor 3
8 ×	<10 ⁸ ⊣		8×10 ⁸ ٦		5×10 ⁸ т	

Adipose tissue



Conclusion

- The novel CliniMACS Prodigy[®] Adherent Cell Culture System enables semi-automated cultivation of adherent cells in a closed system.
- MSCs from three different tissue types (bone marrow, umbilical cord, and adipose tissue) were expanded within this system. Automated expansion by the CliniMACS Prodigy Adherent Cell Culture System and manual expansion using standard tissue culture vessels led to comparable results.
- MSCs were expanded for at least two passages, which was sufficient to harvest clinically relevant numbers in up to 18 days. This time frame included the automated processing of bone marrow aspirate using a density gradient centrifugation within the system.
- The MSC-Brew GMP Medium used in this process is xeno-free and meets the recommendations of USP <1043> on ancillary materials.



References ¹Dominici, M. *et al.*(2006) Cytotherapy 8: 315–317.

Funding

iCARE has received funding from the German Federal Ministry of Education and Research (Fkz01EK1601D)

Integrated Research and Treatment Center Transplantation has received funding from the German Federal Ministry of Education and Research (IFB-Tx, Ref. No. 01EO0802 and 01EO1302)

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS[®] GMP Products are for research use and *ex vivo* cell culture processing only, and are not intended for human *in vivo* applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The CliniMACS[®] System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.

In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. CliniMACS, CliniMACS Product, MACS, MACS, and the MACS logo are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in various countries worldwide. Ficoll-Paque is a trademark of GE Healthcare companies. All other trademarks mentioned in this document are the property of their respective owners and are used for identification purposes only. Copyright © 2019 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.